12.89

2.71% 0.34

Neuropace Inc (NPCE)

Overview News Price History Financials Discussions Forecast

Neuropace Inc stock is traded at $12.89, with a volume of 188.02K. It is up +2.71% in the last 24 hours and up +10.45% over the past month. NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Previous Close:

$12.55

Open:

$12.6

24h Volume:

188.02K

Relative Volume:

0.84

Market Cap:

$392.38M

Revenue:

$65.42M

Net Income/Loss:

$-32.96M

P/E Ratio:

-10.15

EPS:

-1.27

Net Cash Flow:

$-19.87M

1W Performance:

+7.60%

1M Performance:

+10.45%

6M Performance:

+71.64%

1Y Performance:

+61.73%

1-Day Range:

$12.52

$13.19

1-Week Range:

$11.19

$13.19

52-Week Range:

$5.45

$15.11

Neuropace Inc Stock (NPCE) Company Profile

Name

Neuropace Inc

Sector

Healthcare (1153)

Industry

Medical Devices (157)

Phone

(650) 237-2700

Address

455 N. BERNARDO AVENUE, MOUNTAIN VIEW

Employee

184

Twitter

Next Earnings Date

2025-03-04

Latest SEC Filings

NPCE's Discussions on Twitter

Compare NPCE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NPCE Neuropace Inc	12.89	392.38M	65.42M	-32.96M	-19.87M	-1.27
ABT Abbott Laboratories	133.24	231.09B	42.34B	13.50B	6.66B	7.71
BSX Boston Scientific Corp	102.86	155.24B	17.55B	2.03B	2.72B	1.37
SYK Stryker Corp	380.92	144.54B	23.22B	2.86B	3.58B	7.40
MDT Medtronic Plc	83.48	108.82B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	73.68	44.31B	5.54B	4.18B	623.10M	7.00

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-21-25	Initiated	UBS	Buy
Mar-14-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-30-24	Initiated	Leerink Partners	Outperform
Nov-10-23	Initiated	Cantor Fitzgerald	Overweight
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-22-23	Initiated	Lake Street	Buy
Apr-06-22	Initiated	Wolfe Research	Outperform
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform
May-17-21	Initiated	JP Morgan	Overweight
May-17-21	Initiated	Morgan Stanley	Overweight
May-17-21	Initiated	SVB Leerink	Outperform
May-17-21	Initiated	Wells Fargo	Overweight

View All

Neuropace Inc Stock (NPCE) Latest News

May 09, 2025

NeuroPace (NPCE) to Release Quarterly Earnings on Wednesday - MarketBeat

May 09, 2025

May 05, 2025

JPMorgan Chase & Co. Purchases 52,829 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat

May 05, 2025

May 04, 2025

Nantahala Capital Management LLC Sells 45,817 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat

May 04, 2025

May 02, 2025

Study: NeuroPace’s Technology Can Help Reduce Epileptic Seizures - Medical Product Outsourcing

May 02, 2025

Apr 30, 2025

28,547 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Purchased by Walleye Capital LLC - MarketBeat

Apr 30, 2025

NeuroPace, Inc. (NASDAQ:NPCE) Shares Acquired by JPMorgan Chase & Co. - Defense World

Apr 30, 2025

Apr 29, 2025

Retail investors who hold 34% of NeuroPace, Inc. (NASDAQ:NPCE) gained 10%, institutions profited as well - simplywall.st

Apr 29, 2025

Apr 28, 2025

Geode Capital Management LLC Has $3.62 Million Stock Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World

Apr 28, 2025

Apr 24, 2025

Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Rises By 45.8% - MarketBeat

Apr 24, 2025

Apr 20, 2025

NeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Growth in Short Interest - Defense World

Apr 20, 2025

Apr 15, 2025